Robert Van Gulick
Overview
Explore the profile of Robert Van Gulick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Turner J, Fredrickson M, DAntonio M, Katsnelson E, Macbeth M, Van Gulick R, et al.
Nat Commun
. 2023 Jun;
14(1):3214.
PMID: 37270644
Lysophosphatidic acid (LPA) is a bioactive lipid which increases in concentration locally and systemically across different cancer types. Yet, the exact mechanism(s) of how LPA affects CD8 T cell immunosurveillance...
2.
Turner J, Paton E, Van Gulick R, Stefanoni D, Cendali F, Reisz J, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565240
There is increasing evidence that oxidative metabolism and fatty acids play an important role in BRAF-driven tumorigenesis, yet the effect of mutation and expression on metabolism is poorly understood. We...
3.
Dart C, Mukherjee N, Amato C, Goulding A, Macbeth M, Van Gulick R, et al.
Pharmaceuticals (Basel)
. 2021 Aug;
14(8).
PMID: 34451846
Although treatment options for melanoma patients have expanded in recent years with the approval of immunotherapy and targeted therapy, there is still an unmet need for new treatment options for...
4.
Newell F, Wilmott J, Johansson P, Nones K, Addala V, Mukhopadhyay P, et al.
Nat Commun
. 2020 Oct;
11(1):5259.
PMID: 33067454
To increase understanding of the genomic landscape of acral melanoma, a rare form of melanoma occurring on palms, soles or nail beds, whole genome sequencing of 87 tumors with matching...
5.
Mukherjee N, Amato C, Skees J, Todd K, Lambert K, Robinson W, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32764384
There is an urgent need to develop treatments for patients with melanoma who are refractory to or ineligible for immune checkpoint blockade, including patients who lack BRAF-V600E/K mutations. This is...
6.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Mukherjee N, Skees J, Todd K, West D, Lambert K, Robinson W, et al.
Cell Death Dis
. 2020 Jun;
11(6):443.
PMID: 32513939
Current treatment for patients with metastatic melanoma include molecular-targeted therapies and immune checkpoint inhibitors. However, a subset of melanomas are difficult-to-treat. These melanomas include those without the genetic markers for...
7.
Turner J, Bemis J, Bagby S, Capasso A, Yacob B, Chimed T, et al.
Oncogene
. 2018 Sep;
38(8):1296-1308.
PMID: 30254212
Oncogenic BRAF fusions have emerged as an alternate mechanism for BRAF activation in melanomas and other cancers. A number of BRAF fusions with different 5' gene partners and BRAF exon...
8.
Van Gulick R
Behav Brain Sci
. 2011 Nov;
34(6):325-6.
PMID: 22074979
The instrumental model offered by Müller & Schumann (M&S) is broadened to apply not only to drugs, but also to other methods of self-control, including the use of mental constructs...